Abstract: The invention provides methods of immunotherapy of Alzheimer's and similar diseases in which the regime administered to a patient depends on the ApoE genotype of the patient.

Abstract: The invention provides methods of immunotherapy of Alzheimer's and similar diseases in which the regime administered is monitored by measuring levels of tau.

Abstract: The invention provides methods of immunotherapy of Alzheimer's and similar diseases in which the regime administered is monitored by measuring levels of tau.

Abstract: The invention provides improved agents and methods for treatment of diseases associated with beta amyloid (A?). Preferred agents include antibodies, e.g., humanized antibodies specific for A?.

Abstract: The invention provides methods of immunotherapy of Alzheimer's and similar diseases in which the regime administered is monitored by measuring levels of tau.

Abstract: The invention provides methods of immunotherapy of Alzheimer's and similar diseases in which the regime administered to a patient depends on the ApoE genotype of the patient.

Abstract: The invention provides methods of immunotherapy of Alzheimer's and similar diseases in which the regime administered to a patient depends on the ApoE genotype of the patient.

Abstract: The invention provides improved agents and methods for treatment of diseases associated with amyloid deposits of A? in the brain of a patient. Preferred agents include antibodies, e.g., humanized antibodies.

Abstract: The invention provides methods of immunotherapy of Alzheimer's and similar diseases in which the regime administered to a patient depends on the ApoE genotype of the patient.

Abstract: The present invention addresses a need in the art for methods of identifying apoptotic proteins and methods for screening compounds which inhibit an apoptotic protein. More particularly, in certain embodiments, the invention relates to increased expression levels of a NALP1 gene and/or a NALP5 gene following neuron injury. In other embodiments, the present invention demonstrates that the recombinant expression of NALP1 and/or NALP5 polynucleotides stimulates apoptosis in cultured neurons, HeLa cells and NIH-3T3 cells. In yet other embodiments, the invention relates to mutations in the nucleotide binding sequence (NBS) of a NALP1 or a NALP5 polypeptide, wherein these NBS mutations inhibit purine nucleotide binding and reduce caspase activation.

Abstract: This application describes a purified and isolated fragment of a nucleic acid molecule encoding an amyloid precursor mutein, wherein the fragment comprises a nucleic acid sequence encoding at least one marker and a nucleic acid sequence of about 419, about 475 or about 494 amino acid residues in which a portion thereof encodes a .beta.-amyloid protein domain. Also described is a method for screening for a compound which reduces the formation of .beta.-amyloid protein.

Abstract: This disclosure concerns a method of detecting the presence of a polypeptide in a sample wherein the polypeptide is encoded by a fragment of a nucleic acid molecule encoding an amyloid precursor mutein and the fragment comprises a sequence encoding at least one marker and a sequence encoding about 419 amino acid residues of the APP-695 isoform, about 475 amino acid residues of the APP-751 isoform or about 494 amino acid residues of the APP-770 isoform. The method encompasses contacting the sample with an antibody, which specifically binds the marker or the amyloid precursor mutein, under suitable conditions to favor the formation of an antibody-antigen complex and detecting the presence of any complex thus formed. The disclosure also deals with the method employing the above nucleic acid fragment wherein the amino acid residues from position 11 to position 28 are deleted from the portion of the sequence encoding the .beta.

Abstract: This application describes a purified and isolated fragment of a nucleic acid molecule encoding an amyloid precursor mutein, wherein the fragment comprises a nucleic acid sequence encoding at least one marker and a nucleic acid sequence of about 419, about 475 or about 494 amino acid residues in which a portion thereof encodes a .beta.-amyloid protein domain. Also described is a method for screening for a compound which reduces the formation of .beta.-amyloid protein.

Abstract: This application describes a purified and isolated fragment of a nucleic acid molecule encoding an amyloid precursor mutein, wherein the fragment comprises a nucleic acid sequence encoding at least one marker and a nucleic acid sequence of about 419, about 475 or about 494 amino acid residues in which a portion thereof encodes a .beta.-amyloid protein domain. Also described is a method for screening for a compound which reduces the formation of .beta.-amyloid protein.